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PIH20
ClInICal and Cost-effeCtIveness of a ProCalCItonIn test as a PromPt 
IndICator of Prodomol menIngoCoCCal dIsease In febrIle CHIldren: 
Cost-effeCtIveness analysIs
Bell J.M.1, Shields M.1, Angus A.2, Dunlop K.3, Bourke T.1, Kee F.1, Lynn F.A.1
1Queen’s University Belfast, Belfast, UK, 2Belfast Health & Social Care Trust, Belfast, UK, 3South 
Eastern Health and Social Care Trust, Belfast, UK
Objectives: To establish if the procalcitonin (PCT) test’s diagnostic performance 
is more clinically and cost-effective than C reactive protein (CRP) and White 
Cell Count (WCC) tests for suspicion of prodomal stage Meningococcal disease 
(MD) in children presenting at emergency department (ED) with a fever without 
source. MethOds: A decision analytic model was designed to reflect realistic 
clinical pathways for a child presenting with non-specific fever to ED. Test accu-
racy was evaluated using data from independent studies carried out in developed 
countries identified through a systematic literature search. Studies were combined 
to determine the optimal cut-off value for the PCT, CRP and WCC tests, each as an 
indicator of MD. Summary Receiver Operator Curve (SROC) analysis was used to 
determine the inter-study and overall diagnostic performance of each test from 
the areas under the curve (AUC), with 95% confidence intervals (CIs). Components 
of each clinical pathway were costed in UK sterling using the National Schedule 
of Reference Costs 2010-2011. Hospital stays were costed using the appropriate 
Health Resource Group code. Results: Seven studies involving 881 children with 
non-specific fever provided data for inclusion. The PCT test was more accurate 
(sensitivity= 89%, 95%CI= 75-96; specificity= 71%, 95%CI= 37-91) for early MD com-
pared to CRP (sensitivity= 84%, 95%CI= 74-90; specificity= 60%, 95%CI= 44-74) and 
WCC (sensitivity= 50%, 95%CI= 39-60; specificity= 68%, 95%CI= 54-79). PCT had the 
best PLR (3.0, 95%CI= 1.8-7.8) to be viable as a rule-in test for MD and a borderline 
NLR as a rule-out test, making it a better option to either CRP (2.1, 95%CI= 1.4-3.1) 
or WCC (1.5, 95%CI= 1.0-2.3). Outcomes from the decision analytic model indicated 
that the PCT test was the most cost-effective (£2547 per patient treated), followed 
by the combined CRP and WCC test (£3069 per patient treated). cOnclusiOns: The 
improved sensitivity and specificity of the PCT test provides a more cost-effective 
test than the currently recommended CRP and WCC tests.
PIH21
Cost-effeCtIveness analysIs In tHe treatment of Heavy menstrual 
bleedIng In sPaIn
Lete I.1, Calaf J.2, Crespo C.3, Canals I.4, Espinós B.4, Cristóbal I.5
1Hospital Santiago Apóstol of Vitoria, Vitoria-Gasteiz, Spain, 2Hospital de la Santa Creu i Sant 
Pau, Barcelona, Spain, 3Oblikue Consulting, Barcelona, Spain, 4Bayer Health Care, Barcelona, 
Spain, 5Hospital Sanitas La Zarzuela, Madrid, Spain
Objectives: To evaluate the cost-effectiveness of first-line treatment of heavy men-
strual Bleeding (HMB) from the perspective of the Spanish National Healthcare 
System. MethOds: A cost-effectiveness analysis was performed using a Markov 
model to simulate the evolution of a cohort of women in reproductive age, with 
HMB and who wish to preserve their fertility status, in a time horizon of 5 years. 
The treatment strategies were levonorgestrel intrauterine system (LNG-IUS), estra-
diol valerate/dienogest (E2V/DNG), combined oral contraceptives (COC) and oral 
progestins (PROG). Clinical data was modelled indirectly combining literature and 
expert opinion. Outcomes were symptom-free months (SFM), quality-adjusted life 
months (QALM) and costs expressed in € in 2012. A probabilistic sensitivity analy-
sis was conducted to examine the robustness of the results. Results: The mean 
treatment cost of HMB at 6 month was 205€ for LNG-IUS, 318€ for E2V/DNG, 412€ 
COC and 766€ PROG. In the analysis over 5 years, LNG-IUS produced savings of 
578€ compared to E2V/DNG, 991€ compared to COC and 1,821€ compared to PROG. 
Regarding the effectiveness, LNG-IUS provided 51.30 SFM, while E2V/DNG, COC and 
PROG provided 50.64, 49.09 and 47.77 SFM, respectively. Moreover, 77%, 65%, 56% and 
46% of the patients treated with LNG-IUS, E2V/DNG, COC and PROG, respectively, 
continued treatment without surgery during the 5 year period. Considering QALM 
as outcome, LNG-IUS and E2V/DNG were the options that yielded more gains in 
QALM (49.71 for LNG-IUS, 48.09 for E2V/DNG, 46.59 for COC and 44.66 for PROG). 
LNG-IUS was the most effective and less costly, therefore dominant option. In the 
oral treatments comparison, E2V/DNG was dominant, providing savings and gains in 
terms of SFM and QALM. The probabilistic sensitivity analysis on the key parameters 
confirmed the robustness of the base case. cOnclusiOns: LNG-IUS is a cost-saving 
option for the treatment of HMB in Spain. Among oral treatments, E2V/DNG is also 
a dominant strategy.
PIH22
systematIC lIterature revIew and Cost-effeCtIveness analysIs of 
fetal fIbroneCtIn test for PredICtIng Preterm In brazIl
Decimoni T.C.1, Sansone D.1, Etto H.1, Santos A.M.1, Araújo G.2, Fonseca E.S.2, Fonseca M.2
1Axia.Bio Consulting, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, 
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Objectives: Brazil is among the countries with the highest incidence of preterm 
births. Incorporation of diagnostic tests to predict a preterm birth could improve 
the efficiency of the clinical practice reducing hospital expenses related to mater-
nal hospitalization. The aim of this study was to compare the cost-effectiveness 
of fibronectin testing (FN) vs cervical length (CL) measurement in women with 
symptomatic preterm labor. MethOds: Systematic review of the literature of the 
diagnostic tests and development of a decision analytic model using the accuracy of 
the diagnostic tests to predict preterm birth and project the results in terms of effec-
tiveness and cost. The analysis was performed for a hypothetical cohort of 10,000 
patients, for each test, with symptomatic preterm labor between 24 and 34 weeks of 
gestation. The primary perspective of the study was of the Brazilian Health system 
(SUS). Data sources were the medical literature, SUS official published prices for 
medicines and DATASUS (SUS database). Costs are in 2012 Brazilian Reais. Results: 
A total of 14 studies were included. There was a wide variation concerning the accu-
racy of the tests among the studies, particularly with respect to gestational age at 
Objectives: To predict the cost of a delivery following assisted reproductive 
technologies (ART) in Poland. Moreover, the cumulated in vitro fertilization (IVF) 
effectiveness ratio was calculated and the costs of drugs for each of the three 
stimulation protocols used in IVF (long with GnRH agonist, short with GnRH 
antagonist and short with GnRH agonist) were estimated. MethOds: In order to 
calculate the IVF effectiveness, a pooled analysis of the results from European IVF 
monitoring reports concerning Poland from 2008 to 2010 was performed. Costs of 
the clinical and biotechnological parts of IVF were based on the Ministry of Health 
calculation. Drugs’ costs were estimated considering both dosages based on the 
Summaries of Products Characteristics and the retail prices. Costs were calculated 
based on identified costs in both the patient and payer perspectives. Results: 
The overall birth rate per cycle was 21,70%. The probability of a delivery was 
1,5 higher during fresh cycle than in frozen embryo transfer. A total of 24,09% 
of embryo transfers resulted in delivery. The cost of drugs used during ovarian 
stimulation protocol was estimated on 6 055 PLN. The average cost per cycle was 13 
565 PLN. Drugs account for 45% of this value. The average cost per birth was 42 848 
PLN. cOnclusiOns: In vitro fertilization is an expensive procedure for a patient 
in Poland. It is due to a limited effectiveness, usually requiring several repeats of 
the whole cycle of IVF with no drugs reimbursement. The ovarian stimulation is 
the most expensive part of the procedure. Thus, reimbursement of medication 
should also be established.
PIH18
Cost-effeCtIveness of maternal toxoPlasma sCreenIng In austrIa: a 
deCIsIon-analytIC model
Prusa A.R.1, Walter E.2, Pollak A.1, Hayde M.1, Kasper D.C.1
1Medical University of Vienna, Vienna, Austria, 2Institute for Pharmaeconomic Research, Vienna, 
Austria
Objectives: Toxoplasma infection during pregnancy presents a serious hazard 
to the fetus including lifelong disabilities of connatal infected children. This 
foodborne illness is a common burden worldwide. Prevention strategies of the 
health care providers are diverse. In Austria, the maternal toxoplasma screening 
has been implemented four decades ago. The aim of this study was to deter-
mine cost-effectiveness of the maternal toxoplasma screening. MethOds: We 
developed a two arm decision-analytic model. One arm of the model assessed 
the costs and consequences of no prevention, while the other one evaluated 
the screening. The study population included pregnant women and offspring 
screened and treated for toxoplasma infection. The average number of births 
was 76,547 and 50,000 pregnant women were susceptible to infection. The 
analysis focused on lifetime consequences of the connatal infection. This 
encompassed direct costs (screening, cost of illness, maternal and pediatric 
treatment), indirect costs (changed job situation of parents, human-capital of 
dead individuals, blindness and special schools), quality-adjusted-life-years 
(QALYs) and reduced expectation of life. Costs were presented per child and 
for the Austrian birth cohort. Costs from published sources were used (2012 
Euro) from the societal perspective. QALYs, life-years (LYs) and costs were pro-
jected over a life-time horizon and discounted at 3% p.a. Results: Maternal 
toxoplasma screening reduced transmission risk by 40% and one quarter of 
affected children showed symptoms. We found five-times higher lifetime costs 
per child without prevention compared to screening. Also direct costs were 
lower in the latter group; screening costs did not offset costs of sequelae. A split 
in direct and indirect costs components demonstrated that proportion of direct 
costs without prevention amounted to 20% and 95% with screening. Screening 
resulted in QALYs gained and LYs saved. cOnclusiOns: Funding the maternal 
toxoplasma screening saves money and is cost-effective for the society and the 
Austrian health care system.
PIH19
Cost-effeCtIveness of unIversal PaedIatrIC rotavIrus vaCCInatIon 
wItH rIx4414 In greeCe
Karabela P.1, Efklidou E.1, Lyberopoulou E.1, Panagopoulou C.1, Standaert B.2
1GlaxoSmithKline, Halandri, Greece, 2GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: Rotavirus gastroenteritis is a major health burden in young chil-
dren worldwide. This study investigates the cost-effectiveness of universal pae-
diatric rotavirus vaccination with RIX4414, a two-dose human rotavirus vaccine, 
in Greece. MethOds: A Markov cohort model with a cycle time of one month 
was constructed in Microsoft Excel. The birth cohort of 114,766 infants, based 
on 2010 official registry was entered into the model and followed over average 
life expectancy with acute rotavirus events measured up to five years of age. 
Probabilities, utility scores and costs for hospitalisations, hospital-acquired 
rotavirus infection, medical consultations, emergency visits and deaths due to 
rotavirus were taken from published sources and national databases. Costs and 
benefits were reported at 2012 euros, discounted at 3% and 1.5% respectively 
per year and compared between a vaccinated and unvaccinated cohort from 
a Social Sick-Fund perspective. Results: Vaccination with RIX4414 incurred 
an incremental cost of € 16,569 per QALY at a price of € 48/dose. The estimated 
number of rotavirus-related diarrhoea events per year up to the age of five is 
45,906. Total direct medical cost of rotavirus disease without vaccination is 
around € 8,980,000 per year in Greece. Vaccination (40% coverage) reduces the 
number of gastro-enteritis events by 27% to 33,492 and the number of rotavirus-
related medical visits from 17,214 per year to less than 11,000. Total cost of 
rotavirus disease, including the costs of vaccination, in the vaccinated cohort 
is estimated at € 10,087,614 per year, with a cost reduction on direct medical 
costs of € 3,343,781. This cost reduction reflects the high financial disease burden 
related to the medical visits including paediatricians, emergency and hospital 
visits. cOnclusiOns: Paediatric vaccination against rotavirus with RIX4414 
versus no vaccination in Greece improves health outcomes, reduces direct medi-
cal costs and is cost-effective from a social sick fund perspective.
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respectively. Cost-effectiveness ratio was $ 88.7 for oxyprogesteronicaproas and $ 
80.9 for dydrogesterone. cOnclusiOns: Cost-effectiveness analysis shown, that 
the use of dydrogesterone is more effective and less costly for threatened abortion 
treatment in Ukraine. The results of pharmacoeconomic analysis will optimize the 
government, insurance companies and patients cost.
PIH26
Cost-effeCtIveness of Infant PneumoCoCCal vaCCInatIon In tHe 
netHerlands
Vemer P.1, Postma M.J.2
1UMC Groningen, Groningen, The Netherlands, 2University of Groningen, Groningen, The 
Netherlands
Objectives: The Dutch National Immunization Program offers the 10-valent pneu-
mococcal conjugate vaccine (PCV10). Also licensed for use in the infant population 
is the 13-valent PCV (PCV13). To update cost-effectiveness (CE) estimates of PCV13 
over PCV10, using current epidemiological and economic data. MethOds: We mod-
eled vaccinating a birth cohort with either PCV10 or PCV13 (3+1 dose schedule), and 
calculated costs and effects linked to resulting disease. We modeled invasive pneu-
mococcal disease (IPD), non-invasive pneumonia and acute otitis media, and con-
sidered death and lifetime impairments after IPD. We calculated direct effects in 
the vaccinated cohort and indirect effects –herd immunity for the vaccine-type (VT) 
serotypes and replacement for the non-VT serotypes– in the rest of the population. 
Since no price is available, we use a price difference of € 11 per dose and vary this 
price difference in sensitivity analyses. Epidemiological and economic data are taken 
as current as possible. A set of scenarios explore different assumptions, including 
different sets of epidemiological data, assumptions on vaccine efficacy and indirect 
effects. Results: Taking only direct effects into account PCV13 cannot be consid-
ered cost-effective, unless the price difference is much lower than € 11 per dose. In 
three scenarios, PCV10 dominates PCV13; in the other scenarios the ICER is between 
€ 89000 and € 153000 per QALY gained. If indirect effects are also taken into account, 
the ICER of PCV13 compared to PCV10 is below € 20,000 per QALY for all scenarios. 
Scenarios do not have a large impact on the policy decision, unless we assume extra 
efficacy of PCV10 against non-typeable Haemophilus influenzae. cOnclusiOns: 
Replacing PCV10 with PCV13 is not likely to be cost-effective in preventing invasive 
pneumococcal disease in young children. Taking potential benefits in elderly into 
account, PCV13 is likely cost-effective. The CE of PCV13 was highly sensitive for indi-
rect effects our analysis.
PIH27
Cost-mInImIzatIon analysIs of dIenogest versus gonadotroPHIn-
releasIng Hormone analogues or dydrogesterone for 
endometrIosIs treatment In russIa
Avxentyeva M.
The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia
Objectives: To perform pharmacoeconomic evaluation of dienogest vs gonadotro-
phin-releasing hormone analogues (GnRHa) or dydrogesterone for endometriosis in 
Russia. MethOds: Literature search did not reveale clinically significant differences 
in efficacy between dienogest 2 mg and GnRHa in terms of pain reduction associ-
ated with endometriosis. There was no difference in efficacy with dydrogesterone 
60 mg once daily and placebo. Cost-minimization analysis was used to assess and 
compare drug costs of dienogest 2 mg daily, GnRHa - most often used in Russia 
including triptorelin, leuprorelin, buserelin (with obligatory application of add-back 
therapy for all three GnRHa) and dydrogesterone. Costs were calculated for a period 
of 6 months. Results: Costs of endometriosis treatment per patient per 6 months 
were 1102€ for triptorelin, 1118€ for leuprorelin, 340€ for buserelin, 369€ for dydro-
gesterone and 295€ for dienogest. Dydrogesterone is less effective and more costly 
alternative in comparison with buserelin and dienogest. Among alternatives with 
the same efficacy dienogest is the most efficient option leading to savings from 74€ 
to 823€ per patient in 6 months. cOnclusiOns: Using dienogest for treatment of 
endometriosis in Russia is as effective as using GnRHa but can lead to considerable 
cost savings because add-back therapy is not required.
PIH28
Cost mInImIzatIon analysIs of tHe dIenogest use In PatIents wItH 
endometrIs under brazIlIan PublIC and PrIvate PersPeCtIve
Ferracini M., Nakada C.P.
Bayer healthcare Brazil, São Paulo, Brazil
Objectives: To provide the results from a cost-minimization (CM) model that com-
pares the use of dienogest with the use of GnRH antagonist (GnRHa) leuprorelin 
acetate, both for 6 months, in women with endometriosis-associated pelvic pain 
(EAPP) in Brazil. MethOds: A(CM) model was developed in the form of a decision 
tree to mimic treatment sequence in Brazil. The analysis was conducted under the 
private and public payer perspectives, only direct costs were included, procedures 
and drug costs were obtain from Brazilian official databases of public and private 
health care system fees. This CM model compared different treatment pathways for 
women with EAPP and used a 50% improvement in pelvic pain as a definition of a 
treatment responder to elicit treatment duration. Treatment response assessment 
was at 12 week period. Two basic treatment pathways were defined: a two treatment 
sequence (2TS) and tree treatment sequence (3TS). The 2TS consists of: GnRHa/dien-
ogest followed by surgery. The 3TS consists of: GnRHa/dienogest, dienogest/GnRH 
as second treatment and surgery as final option. Subsequent treatments were only 
for patients that did not respond to previous treatment. Discount was not applied 
as costs occurred within 1 year period. Results: The CM model shows that for 
both treatment pathways and perspectives dienogest is a cost-saving alternative. 
Under private payer perspective for 2TS and 3TS: BRL 1020.42 VS BRL 2328.94 and 
BRL 1461.22 VS BRL 2377.52 for dienogest and GnRHa respectively. Under public 
payer perspective for 2TS and 3TS: BRL 882.74 VS BRL 768.13 and BRL 942.18 VS BRL 
856.77 for dienogest and GnRHa respectively. Efficacy for 2TS and 3TS are: 91.58% 
testing/delivering and definition of the CL test threshold. The values obtained were 
LR+ 3,98/LR- 0,33 (FN) and LR+ 2,22/LR- 0,54 (CL). For the whole hypothetical cohort 
the total costs of the FN and CL were 2,3 billion and 890 million, respectively. The 
difference of avoided hospitalizations between the tests was 244 for FN. ICER was 
BRL 5,834,35. cOnclusiOns: Both diagnostic tests are important alternatives for 
the detection of premature birth in Brazil. Studies of prediction of preterm delivery 
using CL have important limitations beyond the fact that CL measure is an operator/
machine dependent procedure. In women with symptomatic preterm labor FN is a 
cost-effective test strategy for prediction of preterm births.
PIH23
Cost-effeCtIveness of vaCCInatIon agaInst HerPes zoster and 
PostHerPetIC neuralgIa: a CrItICal revIew
Kawai K.1, Préaud E.2, Baron-Papillon F.2, Acosta C.J.1
1Merck & Co., Inc, West Point, PA, USA, 2Sanofi Pasteur MSD, Lyon, France
Objectives: To systematically review cost-effectiveness studies of vaccination 
against herpes zoster (HZ) and post-herpetic neuralgia (PHN). MethOds: We 
searched MEDLINE and EMBASE databases for eligible studies until June 2013. We 
extracted information regarding model structure, model input parameters, and 
study results. We compared the results across studies by projecting the health and 
economic impacts of vaccinating 1 million adults over their lifetimes. Results: We 
identified 14 cost-effectiveness studies performed in North America and Europe. 
Results ranged from approximately US$10,000 to US$100,000 per quality-adjusted 
life years gained, though most studies in Europe concluded that zoster vaccination 
is likely to be cost-effective. All studies used similar model structure. Differences 
in results among studies are largely due to differing assumptions regarding dura-
tion of vaccine protection and a loss in quality of life associated with HZ and to 
a larger extent, PHN. In addition, studies found that vaccine efficacy against PHN, 
age at vaccination, and vaccine cost strongly influenced the results in sensitiv-
ity analysis. cOnclusiOns: Our review generally supports the economic value of 
this preventive intervention, particularly in Europe, which will become increasingly 
important as population ages. Future research addressing key model parameters 
and cost-effectiveness studies in other parts of the world are needed.
PIH24
an eConomIC evaluatIon alongsIde a ClInICal trIal (eeaCt) In PelvIC 
floor medICIne
Brennan V.K.1, Dixon S.2, Jones G.2, Radley S.3, Jacques R.2, Wood H.2, Ledger W.4
1RTI Health Solutions, Sheffield, UK, 2University of Sheffield, Sheffield, UK, 3Sheffield Teaching 
Hospitals Charitable Trust, Sheffield, UK, 4University of New South Wales, Sydney, Australia
Objectives: To determine the cost-effectiveness of using an online questionnaire 
(ePAQ-PF) in combination with a telephone consultation compared to standard 
care. MethOds: All women, aged ≥ 18 years and referred to urogynaecology ser-
vices in Sheffield were eligible. Women completed ePAQ-PF online and then received 
a telephone consultation (intervention), or face-to-face consultation (standard 
care). Costs for ePAQ-PF completion and consultation were derived in a microcost-
ing study. Resource use data were collected at 6-months follow-up. The SF-12 was 
administered at baseline and follow-up. SF-6D estimates were used to calculate 
quality-adjusted life-years (QALYs). Patient experience was measured by the Patient 
Experience Questionnaire and Client Satisfaction Questionnaire. Results: A total of 
195 women were randomised. Consultation costs for the intervention group (£31.75) 
were lower than for the control (£72.17). The intervention group incurred greater 
direct costs and personal expenditure during follow-up. However lower costs asso-
ciated with productivity loss for the intervention group resulted in lower indirect 
costs per-patient. Mean total costs per-patient were £38.04 greater in the intervention 
group (£1,139.86) than the control (£1101.82). SF-6D scores reduced slightly during 
follow-up for the intervention group, and increased slightly for the control, resulting 
in QALY loss for the intervention group, and QALY gains for the control. Statistically 
significant gains in patient experience were identified for the intervention group, 
although in strict cost-utility terms the intervention was dominated by the control. 
Incremental costs and QALYs resulted in a negative incremental cost-effectiveness 
ratio (ICER). cOnclusiOns: Although the intervention was not cost-effective com-
pared to the controls, there was a significant difference in an important aspect of the 
care process, which was not captured by the ICER. This highlights the importance of 
decision makers accounting for intervention effects that fall outside the conventional 
conceptualization of the QALY. Methods could be developed that allow non-health 
effects, such as process utility, to be incorporated into the QALY.
PIH25
PHarmaCoeConomIC analysIs of Progestogen PreParatIons for 
tHreatened abortIon treatment In ukraIne
Tkachova O.1, Iakovlieva L.1, Mishchenko O.1, Matyashova N.2
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Kharkiv, 
Ukraine
Objectives: Comparative evaluation the cost effectiveness of threatened abor-
tion treatment by two regimens: oxyprogesteronicaproas and dydrogesterone in 
Ukraine. MethOds: Pharmacoeconomic analysis was based on the results of com-
parative randomized trial (Belousov Yu. B., Karpov O.I., Ailamazian E.K., 2008). Two 
regimens for threatened abortion treatment: oxyprogesteronicaproas and dydroges-
terone were evaluated. Treatment with dydrogesterone (20 mg per day or 2 tablets 
per day) was carried out during 8 weeks before closure forming placenta (56 days). 
Oxyprogesteronicaproas (250 mg per day) was used from 14 to 20 weeks of gestation 
(42 days). For determining the cost of therapy only the cost of drugs and auxiliary 
materials (syringes, alcohol) for both schemes were taken into account. The prices 
of drugs were taken from the information system “Drugs” of Company “Morion” 
(February, 2013, Ukraine). The currency ratio of UAH to dollar (USA) on 01.02.13 was 
8,12:1. As an indicator of efficacy the number of saved pregnancy after treatment 
was used. Results: The effectiveness of oxyprogesteronicaproas therapy was 
88.6%, and dydrogesterone - 96.3%, the cost of treatment was $ 78.63 and $ 77.96 
